Reward-Induced Eating: Therapeutic Approaches to Addressing Food Cravings

Advances in Therapy

Volumn 33, Issue 11, 2016, Pages 1853-1866

  Rebello, Candida J ^a   Greenway, Frank L ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Appetite; Food cravings; Pharmacology; Reward related eating

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; LORCASERIN; NALTREXONE; PHENTERMINE; SEROTONIN;

ASSOCIATION; ENERGY BALANCE; ENERGY METABOLISM; FEEDING BEHAVIOR; FOOD CRAVING; FOOD INTAKE; HUMAN; MOTIVATION; NONHUMAN; OBESITY; OVERNUTRITION; PERCEPTION; REVIEW; REWARD; REWARD INDUCED EATING; CRAVING; FOOD PREFERENCE; METABOLISM; PHYSIOLOGY; PSYCHOLOGY;

CRAVING; ENERGY METABOLISM; FEEDING BEHAVIOR; FOOD PREFERENCES; HUMANS; OBESITY; REWARD;

EID: 84990976031     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-016-0414-6     Document Type: Review

References (94)

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–128.
2. Singh GM, Danaei G, Farzadfar F, et al. The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis. PLoS One. 2013;8(7):e65174.
3. Prospective Studies C, Whitlock G, Lewington S, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083–96.
4. Emerging Risk Factors C, Wormser D, Kaptoge S, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011;377:1085–95.
5. Lu Y, Hajifathalian K, Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration, et al. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants. Lancet. 2014;383:970–83.
6. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444:875–80.
7. Jequier E, Tappy L. Regulation of body weight in humans. Physiol Rev. 1999;79(2):451–80.
8. Pelchat ML. Food cravings in young and elderly adults. Appetite. 1997;28:103–13.
9. Hill AJ. The psychology of food craving. Proc Nutr Soc. 2007;66:277–85.
10. Swinburn BA, Sacks G, Hall KD, et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet. 2011;378:804–14.
11. Cohen DA. Neurophysiological pathways to obesity: below awareness and beyond individual control. Diabetes. 2008;57:1768–73.
12. Blundell JE, Lawton CL, Cotton JR, Macdiarmid JI. Control of human appetite: implications for the intake of dietary fat. Annu Rev Nutr. 1996;16:285–319.
13. Blundell J. Pharmacological approaches to appetite suppression. Trends Pharmacol Sci. 1991;12:147–57.
14. Berthoud HR. Interactions between the “cognitive” and “metabolic” brain in the control of food intake. Physiol Behav. 2007;91:486–98.
15. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature. 2000;404:661–71.
16. Cone RD, Cowley MA, Butler AA, Fan W, Marks DL, Low MJ. The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int J Obes Relat Metab Disord. 2001;25(Suppl 5):S63–7.
17. Buhmann H, le Roux CW, Bueter M. The gut-brain axis in obesity. Best Pract Res Clin Gastroenterol. 2014;28:559–71.
18. Murphy KG, Bloom SR. Gut hormones and the regulation of energy homeostasis. Nature. 2006;444:854–9.
19. Suzuki K, Simpson KA, Minnion JS, Shillito JC, Bloom SR. The role of gut hormones and the hypothalamus in appetite regulation. Endocr J. 2010;57:359–72.
20. Woods SC, Langhans W. Inconsistencies in the assessment of food intake. Am J Physiol Endocrinol Metab. 2012;303:E1408–18.
21. Blundell JE, Levin F, King NA, et al. Overconsumption and obesity: peptides and susceptibility to weight gain. Regul Pept. 2008;149:32–8.
22. Zheng H, Lenard NR, Shin AC, Berthoud HR. Appetite control and energy balance regulation in the modern world: reward-driven brain overrides repletion signals. Int J Obes (Lond). 2009;33(Suppl 2):S8–13.
23. Kelley AE, Berridge KC. The neuroscience of natural rewards: relevance to addictive drugs. J Neurosci. 2002;22:3306–11.
24. Finlayson G, King N, Blundell JE. Liking vs. wanting food: importance for human appetite control and weight regulation. Neurosci Biobehav Rev. 2007;31:987–1002.
25. Mogenson GJ, Jones DL, Yim CY. From motivation to action: functional interface between the limbic system and the motor system. Prog Neurobiol. 1980;14:69–97.
26. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature. 2006;443:289–95.
27. Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res. 2014;84:1–11.
28. Berridge KC, Robinson TE. Parsing reward. Trends Neurosci. 2003;26:507–13.
29. Hallam J, Boswell RG, DeVito EE, Kober H. Gender-related differences in food craving and obesity. Yale J Biol Med. 2016;89:161–73.
30. Weingarten HP, Elston D. Food cravings in a college population. Appetite. 1991;17:167–75.
31. Zellner DA, Garriga-Trillo A, Rohm E, Centeno S, Parker S. Food liking and craving: a cross-cultural approach. Appetite. 1999;33:61–70.
32. Drewnowski A. Metabolic determinants of binge eating. Addict Behav. 1995;20:733–45.
33. Boswell RG, Kober H. Food cue reactivity and craving predict eating and weight gain: a meta-analytic review. Obes Rev. 2016;17:159–77.
34. Meule A, Lutz A, Vogele C, Kubler A. Food cravings discriminate differentially between successful and unsuccessful dieters and non-dieters. Validation of the Food Cravings Questionnaires in German. Appetite. 2012;58:88–97.
35. Noori HR, Cosa Linan A, Spanagel R. Largely overlapping neuronal substrates of reactivity to drug, gambling, food and sexual cues: a comprehensive meta-analysis. Eur Neuropsychopharmacol. 2016;26:1419–30.
36. Tang DW, Fellows LK, Small DM, Dagher A. Food and drug cues activate similar brain regions: a meta-analysis of functional MRI studies. Physiol Behav. 2012;106:317–24.
37. Edwards CA, Johnson IT, Read NW. Do viscous polysaccharides slow absorption by inhibiting diffusion or convection? Eur J Clin Nutr. 1988;42:307–12.
38. Berthoud HR. Metabolic and hedonic drives in the neural control of appetite: who is the boss? Curr Opin Neurobiol. 2011;21:888–96.
39. la Fleur SE, van Rozen AJ, Luijendijk MC, Groeneweg F, Adan RA. A free-choice high-fat high-sugar diet induces changes in arcuate neuropeptide expression that support hyperphagia. Int J Obes (Lond). 2010;34:537–46.
40. Edwards A, Abizaid A. Driving the need to feed: insight into the collaborative interaction between ghrelin and endocannabinoid systems in modulating brain reward systems. Neurosci Biobehav Rev. 2016;66:33–53.
41. Potenza MN, Grilo CM. How relevant is food craving to obesity and its treatment? Front Psychiatry. 2014;5:164.
42. Dalton M, Finlayson G, Hill A, Blundell J. Preliminary validation and principal components analysis of the Control of Eating Questionnaire (CoEQ) for the experience of food craving. Eur J Clin Nutr. 2015;69:1313–7.
43. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595–605.
44. Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21:935–43.
45. White MA, Whisenhunt BL, Williamson DA, Greenway FL, Netemeyer RG. Development and validation of the food-craving inventory. Obes Res. 2002;10:107–14.
46. Stunkard AJ, Messick S. The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res. 1985;29:71–83.
47. Cepeda-Benito A, Gleaves GH, Williams TL, Erath SA. Development and validation of the state and trait food cravings questionnaire. Behav Ther. 2000;31:151–73.
48. Nijs IM, Franken IH, Muris P. The modified Trait and State Food-Cravings Questionnaires: development and validation of a general index of food craving. Appetite. 2007;49:38–46.
49. Long CG, Blundell JE, Finlayson G. A systematic review of the application and correlates of YFAS-diagnosed ‘food addiction’ in humans: are eating-related ‘addictions’ a cause for concern or empty concepts? Obes Facts. 2015;8:386–401.
50. Tricomi E, Lempert KM. Value and probability coding in a feedback-based learning task utilizing food rewards. J Neurophysiol. 2015;113:4–13.
51. Rolls ET, McCabe C. Enhanced affective brain representations of chocolate in cravers vs. non-cravers. Eur J Neurosci. 2007;26:1067–76.
52. Greenway FL, PIlson R, Ma T, Fain R. The impact of weight loss therapy on control of eating: an exploratory analysis from a 12-week pilot safety study. Obesity Society (TOS). 2015; Abstract. T-P-3153, Available at http://2015.obesityweek.com/app/uploads/2015/11/1104-Wednesday-ObesityWeek-2015-TOS-Poster-Abstracts.pdf. Accessed 4 Oct 2016.
53. Greenway FL, PIlson R, Ma T, Fain R. The impact of weight loss therapy on food cravings: an exploratory analysis from a 12-week pilot safety study with lorcaserin and phentermine. Obesity Week (TOS). 2015; Abstract. T-P-3154, Available at http://2015.obesityweek.com/app/uploads/2015/11/1104-Wednesday-ObesityWeek-2015-TOS-Poster-Abstracts.pdf. Accessed 4 Oct 2016.
54. Package Inserts. http://general.takedapharm.com/content/file.aspx?filetypecode=CONTRAVEPI&cacheRandomizer=eedcee06-8dad-4cf0-910b-06e13004a474 Accessed 17 Aug 2016.
55. Foley KF, DeSanty KP, Kast RE. Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother. 2006;6:1249–65.
56. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995;56:395–401.
57. Anton RF. Naltrexone for the management of alcohol dependence. N Engl J Med. 2008;359:715–21.
58. Johansson BA, Berglund M, Lindgren A. Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction. 2006;101:491–503.
59. Nestler EJ, Carlezon WA Jr. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry. 2006;59:1151–9.
60. Reece AS. Hypothalamic opioid-melanocortin appetitive balance and addictive craving. Med Hypotheses. 2011;76:132–7.
61. Yeomans MR, Gray RW. Effects of naltrexone on food intake and changes in subjective appetite during eating: evidence for opioid involvement in the appetizer effect. Physiol Behav. 1997;62:15–21.
62. Yeomans MR, Gray RW. Selective effects of naltrexone on food pleasantness and intake. Physiol Behav. 1996;60:439–46.
63. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19:110–20.
64. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:342–62.
65. Package Insert. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/085128s065lbl.pdf. Accessed 17 Aug 2016.
66. Moldovan CP, Weldon AJ, Daher NS, et al. Effects of a meal replacement system alone or in combination with phentermine on weight loss and food cravings. Obesity (Silver Spring). 2016. doi:10.1002/oby.21649.
67. Nonogaki K, Strack AM, Dallman MF, Tecott LH. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat Med. 1998;4:1152–6.
68. Heisler LK, Cowley MA, Tecott LH, et al. Activation of central melanocortin pathways by fenfluramine. Science. 2002;297:609–11.
69. Heisler LK, Jobst EE, Sutton GM, et al. Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Neuron. 2006;51:239–49.
70. Lam DD, Przydzial MJ, Ridley SH, et al. Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology. 2008;149:1323–8.
71. Package Insert (Belviq). http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022529lbl.pdf. Accessed 17 Aug 2016.
72. O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20:1426–36.
73. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245–56.
74. Aronne L, Shanahan W, Fain R, et al. Safety and efficacy of lorcaserin: a combined analysis of the BLOOM and BLOSSOM trials. Postgrad Med. 2014;126:7–18.
75. Millan MJ, Dekeyne A, Gobert A. Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology. 1998;37:953–5.
76. Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E. SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology. 1999;38:1195–205.
77. Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E. Biochemical and electrophysiological evidence that RO 60-0175 inhibits mesolimbic dopaminergic function through serotonin(2C) receptors. Brain Res. 2000;865:85–90.
78. Higgins GA, Fletcher PJ. Therapeutic potential of 5-HT2C receptor agonists for addictive disorders. ACS Chem Neurosci. 2015;6:1071–88.
79. Neisewander JL, Acosta JI. Stimulation of 5-HT2C receptors attenuates cue and cocaine-primed reinstatement of cocaine-seeking behavior in rats. Behav Pharmacol. 2007;18:791–800.
80. Grottick AJ, Fletcher PJ, Higgins GA. Studies to investigate the role of 5-HT(2C) receptors on cocaine- and food-maintained behavior. J Pharmacol Exp Ther. 2000;295:1183–91.
81. Higgins GA, Silenieks LB, Rossmann A, et al. The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control. Neuropsychopharmacology. 2012;37:1177–91.
82. Farr OM, Sofopoulos M, Tsoukas MA, et al. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. Diabetologia. 2016;59:954–65.
83. van Bloemendaal L, IJzerman RG, Ten Kulve JS, et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes. 2014;63:4186–96.
84. van Bloemendaal L, Veltman DJ, Ten Kulve JS, et al. Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans. Diabetes Obes Metab. 2015;17:878–86.
85. ten Kulve JS, Veltman DJ, van Bloemendaal L, et al. Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes. Diabetologia. 2015;58:2688–98.
86. Package Insert Liraglutide. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321Orig1s000lbl.pdf. Accessed 17 Aug 2016.
87. Corbetta M, Shulman GL. Control of goal-directed and stimulus-driven attention in the brain. Nat Rev Neurosci. 2002;3:201–15.
88. Farr OM, Tsoukas MA, Triantafyllou G, et al. Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: a randomized, placebo-controlled, crossover study. Metabolism. 2016;65:945–53.
89. Reichelt AC, Westbrook RF, Morris MJ. Integration of reward signalling and appetite regulating peptide systems in the control of food-cue responses. Br J Pharmacol. 2015;172:5225–38.
90. Albertsson PA, Kohnke R, Emek SC, et al. Chloroplast membranes retard fat digestion and induce satiety: effect of biological membranes on pancreatic lipase/co-lipase. Biochem J. 2007;401:727–33.
91. Rebello CJ, Chu J, Beyl R, Edwall D, Erlanson-Albertsson C, Greenway FL. Acute effects of a Spinach extract rich in thylakoids on satiety: a randomized controlled crossover trial. J Am Coll Nutr. 2015;34:470–7.
92. Stenblom EL, Egecioglu E, Landin-Olsson M, Erlanson-Albertsson C. Consumption of thylakoid-rich spinach extract reduces hunger, increases satiety and reduces cravings for palatable food in overweight women. Appetite. 2015;91:209–19.
93. Montelius C, Erlandsson D, Vitija E, Stenblom EL, Egecioglu E, Erlanson-Albertsson C. Body weight loss, reduced urge for palatable food and increased release of GLP-1 through daily supplementation with green-plant membranes for three months in overweight women. Appetite. 2014;81:295–304.
94. Stenblom EL, Montelius C, Erlandsson D, et al. Decreased urge for palatable food after a two-month dietary intervention with green-plant membranes in overweight women. Obesity Weight Loss Therapy. 2014;4:238.